Sagimet Biosciences (SGMT) Accumulated Expenses (2022 - 2026)

Sagimet Biosciences' Accumulated Expenses history runs 5 years deep, the most recent figure standing at $579000.0 for Q1 2026.

• On a quarterly basis, Accumulated Expenses rose 36.88% year-over-year to $579000.0 in Q1 2026; TTM through Mar 2026 was $579000.0, a 36.88% increase from a year earlier, with the FY2025 full-year figure at $3.7 million, up 25.86% from the prior year.
• Accumulated Expenses fell to $579000.0 in Q1 2026 per SGMT's latest filing, from $3.7 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $5.4 million in Q4 2023 and bottomed at $423000.0 in Q1 2025.
• The 5-year median for Accumulated Expenses is $3.2 million (2023), against an average of $2.8 million.
• Biggest YoY gain for Accumulated Expenses was 381.21% in 2025; the steepest drop was 89.3% in 2025.
• Year by year, Accumulated Expenses stood at $4.0 million in 2022, then jumped by 34.37% to $5.4 million in 2023, then tumbled by 45.38% to $3.0 million in 2024, then advanced by 25.86% to $3.7 million in 2025, then tumbled by 84.41% to $579000.0 in 2026.
• Per Business Quant, the three latest SGMT Accumulated Expenses figures stand at $579000.0 (Q1 2026), $3.7 million (Q4 2025), and $4.8 million (Q3 2025).